4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Income from Continuing Operations of 94911000.0 for Q1 2026, down 91.98% year-over-year from 1182834617.85 in Q1 2025, and down 626.73% quarter-over-quarter from 18019000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Income from Continuing Operations for 7 consecutive years, with 94911000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 91.98% year-over-year to 94911000.0; the TTM figure through Mar 2026 stood at 252655000.0 (down 13.1% YoY), while the FY2025 annual figure was 298627000.0, down 3.38% from the prior year.
- Income from Continuing Operations slipped to 94911000.0 in Q1 2026 per FDMT's latest filing, from 18019000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 18019000.0 in Q4 2025 and bottomed at 94911000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 48399470.59 across 5 years, with a median of 47319000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 217.09% — and 2025, when it jumped 135.65%.
- 4D Molecular Therapeutics' Income from Continuing Operations stood at 30282000.0 in 2022, then dropped by 9.21% to 33072000.0 in 2023, then tumbled by 52.85% to 50550000.0 in 2024, then surged by 135.65% to 18019000.0 in 2025, then plunged by 626.73% to 94911000.0 in 2026.
- Business Quant data shows FDMT's Income from Continuing Operations at 94911000.0 in Q1 2026, 18019000.0 in Q4 2025, and 85876000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -97.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -97.49 Mn |
| Mar 31, 2026 | -94.91 Mn |
| Dec 31, 2025 | 18.02 Mn |
| Sep 30, 2025 | -85.88 Mn |
| Jun 30, 2025 | -89.89 Mn |
| Mar 31, 2025 | -49.44 Mn |
| Dec 31, 2024 | -50.55 Mn |
| Sep 30, 2024 | -77.95 Mn |
| Jun 30, 2024 | -45.45 Mn |
| Mar 31, 2024 | -39.06 Mn |
| Dec 31, 2023 | -33.07 Mn |
| Sep 30, 2023 | -29.08 Mn |
| Jun 30, 2023 | -51.28 Mn |
| Mar 31, 2023 | -49.29 Mn |
| Dec 31, 2022 | -30.28 Mn |
| Sep 30, 2022 | -47.32 Mn |
| Jun 30, 2022 | -34.23 Mn |
| Mar 31, 2022 | -33.13 Mn |
| Dec 31, 2021 | -26.28 Mn |
| Sep 30, 2021 | -47.53 Mn |